Progressive effects of valsartan compared with amlodipine in prevention of diabetes according to categories of diabetogenic risk in hypertensive patients: The VALUE trial
Autor: | Sverre E. Kjeldsen, Gordon T. Mcinnes, Giuseppe Mancia, Tsushung A. Hua, Stevo Julius, Michael A. Weber, Antonio Coca, Xavier Girerd, Kenneth Jamerson, Pierre Larochelle, Thomas Macdonald, Roland E. Schmieder, M. Anthony Schork, Reuven Viskoper, Jiri Widimský, Alberto Zanchetti, null FOR THE VALUE TRIAL INVESTIGATORS |
---|---|
Rok vydání: | 2008 |
Předmět: |
Blood Glucose
medicine.medical_specialty Diabetes risk Tetrazoles Type 2 diabetes Double-Blind Method Risk Factors Diabetes mellitus Internal medicine Internal Medicine Humans Medicine Amlodipine Antihypertensive Agents Aged business.industry Valine General Medicine Odds ratio Middle Aged medicine.disease Angiotensin II Treatment Outcome Endocrinology Diabetes Mellitus Type 2 Quartile Valsartan Hypertension Multivariate Analysis Regression Analysis Cardiology and Cardiovascular Medicine business Follow-Up Studies medicine.drug |
Zdroj: | Blood Pressure. 17:170-177 |
ISSN: | 1651-1999 0803-7051 |
Popis: | We have previously shown that the angiotensin receptor blocker valsartan is associated with a lower incidence of new-onset type 2 diabetes than that with the calcium-channel antagonist amlodipine in the treatment of hypertensive patients at high cardiovascular risk. We have now investigated the benefits of valsartan vs amlodipine in patients of different categories of diabetogenic risk. Some 9995 patients without diabetes at onset participated in VALUE, with average follow-up of 4.2 years. Predictors of new diabetes were analyzed by stepwise logistic regression. A diabetes risk score for each patient was calculated based on a multivariate model. The risk of developing new diabetes in quartiles of risk for the disease was calculated as an odds ratio (OR) with 95% confidence intervals (CI). New diabetes was reported in 580 (11.5%) patients on valsartan and in 718 (14.5%) patients on amlodipine (p |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |